PARIS--(BUSINESS WIRE)--Regulatory News:
“We are pleased with the positive Phase 3 results for telotristat etiprate released early August, which are an important milestone in our strategy to become global leaders in neuroendocrine tumors.”
Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the third quarter and first nine months of 2015.
Help employers find you! Check out all the jobs and post your resume.
